Baxdela (delafloxacin) / Menarini, Melinta Therap, Ligand - LARVOL DELTA

Real-world effectiveness and safety of delafloxacin for the treatment of bacterial infections in adults: results from the early-DELA study (ESCMID Global 2026) - No abstract available

Clinical • Late-breaking abstract • Real-world • Real-world effectiveness • Real-world evidence • Infectious Disease

pH-dependent resistance evolution of delafloxacin (DLX) and ciprofloxacin (CIP) in Pseudomonas aeruginosa from cystic fibrosis (CF) and non-CF patients (ESCMID Global 2026) - No abstract available

Clinical • Cystic Fibrosis • Genetic Disorders • Immunology • Respiratory Diseases

Unraveling ciprofloxacin and delafloxacin efficacy and resistance evolution at multiple concentrations on Pseudomonas aeruginosa infection dynamics; results from a human bronchial epithelium model (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease

Comparative activity of delafloxacin and linezolid against methicillin-resistant Staphylococcus aureus (MRSA) biofilm: results of an in vitro dynamic model (ESCMID Global 2026) - No abstract available

Preclinical • Infectious Disease

Delafloxacin beyond the label: early clinical experience against fluoroquinolone-resistant infections (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease

In vitro activity of delafloxacin vs ciprofloxacin, levofloxacin and moxifloxacin against MRSA (ESCMID Global 2026) - No abstract available

Preclinical

Activity of ciprofloxacin vs delafloxacin in acidic environments: impact of SOS response inactivation in Escherichia coli (ESCMID Global 2026) - No abstract available

IPT14 - Fluoroquinolones: friends or foes? One size does not fit all (ESCMID Global 2026) - "Expert speakers will review key clinical data, illustrating its performance alongside a discussion of its safety profile, particularly regarding traditional fluoroquinolones. Attendees will gain a clear, evidence-based understanding of how delafloxacin differentiates from other FQs and its potential role in the treatment of ABSSSI."

Infectious Disease

Efficacy and safety of delafloxacin for musculoskeletal infections caused by levofloxacin-resistant Staphylococci: experience from a multi-centre cohort (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease • Musculoskeletal Diseases

Model-integrated evidence for delafloxacin: minimal PBPK simulations and network meta-analysis to support urinary tract infection indication development (ESCMID Global 2026) - No abstract available

Retrospective data • Infectious Disease • Nephrology

Synergistic activity of a phage cocktail and delafloxacin against Pseudomonas aeruginosa biofilms (ESCMID Global 2026) - No abstract available

Delafloxacin: what does a new fluoroquinolone offer? (PubMed, Rev Esp Quimioter) - "Its activity in local acidic environments and biofilms could play a role in the treatment of biofilm-related infections such as osteoarticular and medical device-associated infections, and due to its broad spectrum, it can also be useful in polymicrobial infections. Delafloxacin is an interesting new addition to the therapeutic arsenal against common and difficult-to-treat infections."

Journal • Review • Infectious Disease • Pneumonia • Respiratory Diseases

Synergistic beeswax-based nano-formulation for enhanced chronic wound healing and antibacterial potency. (PubMed, RSC Adv) - "To address these limitations, we developed a novel beeswax-encapsulated emulsified formulation (F4) combining delafloxacin (DLX), lidocaine (LIDO), and sodium hyaluronate (SHA)...F4 also disrupted biofilms at sub-MIC levels (1/16-1/64 MIC), comparable to ciprofloxacin, and achieved complete bactericidal killing of planktonic S. aureus within 12 h at 4× MIC...Cytotoxicity assays confirmed enhanced biocompatibility (CC50: 872.40 µg mL-1), preserving >80% fibroblast viability at therapeutic doses. This multimodal platform concurrently addresses infection control (including biofilm resistance), analgesia, tissue regeneration, and controlled delivery, offering a transformative strategy for chronic wound management."

Journal • Diabetes • Infectious Disease • Metabolic Disorders

In vitro activity of recently introduced Gram-positive-specific antimicrobial agents against Australian methicillin-resistant Staphylococcus aureus isolates. (PubMed, Pathology) - "MIC was determined for ceftaroline, ceftobiprole, tedizolid, dalbavancin, eravacycline, omadacycline, delafloxacin, lefamulin and vancomycin. Susceptibility testing prior to use of delafloxacin, lefamulin and omadacycline should be considered. When the use of these agents becomes commonplace, ongoing monitoring for resistance is recommended."

Journal • Preclinical • Infectious Disease • Pneumonia • Respiratory Diseases

Highly fluorescent method for ultra-sensitive estimation of delafloxacin in human plasma: greenness assessment. (PubMed, BMC Chem) - "The designed approach was validated following the ICH and FDA guidelines, producing a precise analysis of DEL in its tablets and plasma samples with high recovery percentage. The results provide that the method possesses excellent eco-friendly properties, highlighting its strong compatibility with the principles of green chemistry."

Journal

DELA-PLAT: Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections. (clinicaltrials.gov) - P=N/A | N=20 | Not yet recruiting | Sponsor: IRCCS San Raffaele

New trial • Immunology • Infectious Disease • Inflammation • Rheumatology

Delafloxacin's in vitro activity against bacteroides and its potential place in therapy. (PubMed, Enferm Infecc Microbiol Clin (Engl Ed)) - "Given the potent in vitro anaerobic activity and its broad spectrum, delafloxacin may represent a favourable alternative in the treatment of mixed bacterial infections, particularly those involving multidrug-resistant strains."

Journal • Preclinical • Infectious Disease

Novel use of oral delafloxacin monotherapy in staphylococcal prosthetic valve endocarditis: A case report. (PubMed, Infect Med (Beijing)) - "This report describes a novel use of DFX as oral monotherapy in the treatment of staphylococcal prosthetic endocarditis. Prospective data would be useful to identify future opportunities for the use of this new fluoroquinolone in endocarditis both as monotherapy and for oral use,to simplify antibiotic regimen and to improve patients' quality of life and adherence to therapy."

Journal • Monotherapy • Cardiovascular • Infectious Disease • Pneumonia • Respiratory Diseases

Molecular resistance mechanisms to newly approved antibiotics (2017-2025) in WHO priority pathogens. (PubMed, Front Microbiol) - "This review systematically summarizes the molecular resistance mechanisms that World Health Organization (WHO) priority bacterial pathogens have already deployed against the 15 new antibiotics approved between 2017 and 2025, including β-lactam/β-lactamase inhibitors (cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam), tetracycline derivatives (eravacycline, omadacycline), a pleuromutilin (lefamulin), an aminoglycoside (plazomicin), and a fluoroquinolone (delafloxacin). Preserving the efficacy of these essential drugs thus necessitates a multifaceted, globally coordinated "One Health" strategy. Finally, we discuss how the growing complexity of AMR mechanisms is driving the need for advanced diagnostic tools, exploring the pivotal role of bioinformatics and artificial intelligence in predicting resistance and closing knowledge gaps."

Journal • Review

Synthesis of Enduracididine Free Linear Teixobactin Analogs: Molecular Docking, DFT Calculations, and Their Antimicrobial Activities, Bacterial Cell Wall Lysis and Glucose Assay. (PubMed, Curr Med Chem) - "Mass, 1H NMR, and HPLC analysis characterized the synthesized fine TX analogs (TX1-TX5). The DFT and docking studies' electronic characteristic calculations predicted that halogenated (TX1, TX2, and TX4) and methoxy (TX3) substituted analogs have higher stability and electrophilicity, making them suitable agents for antimicrobial activity."

Journal • Infectious Disease

Evaluation of cerebrospinal fluid penetration of delafloxacin in a murine model. (PubMed, Antimicrob Agents Chemother) - "The CSF penetration ratio of delafloxacin was 49%. Cmax/MIC ratios met pharmacokinetic/pharmacodynamic targets for Staphylococcus and Streptococcus spp., but not Enterobacterales."

Journal • Preclinical

In vitro antibiofilm and intracellular activity of delafloxacin against Staphylococcus aureus and Staphylococcus epidermidis in bone and joint infections. (PubMed, Microbiol Spectr) - "The 90% minimal biofilm eradication concentration (MBEC90) of delafloxacin was compared with that of rifampicin, vancomycin, and levofloxacin after a 24-h treatment of biofilm-embedded staphylococci. However, its efficacy against levofloxacin-resistant strains was variable and appeared to be strain-dependent, both in biofilm and intracellular conditions. This study confirms the promising potential of delafloxacin to treat staphylococcal BJIs, but further investigations, including animal models and clinical trials, are needed to better understand its efficacy."

Journal • Preclinical • Infectious Disease

Modulators of gene amplification alter evolution of antibiotic resistance in Staphylococcus aureus. (PubMed, PLoS Genet) - "We previously showed that the opportunistic pathogen Staphylococcus aureus evolves resistance to the dual-targeting fluoroquinolone delafloxacin (DLX) that inhibits both the DNA gyrase and DNA topoisomerase IV via amplification of an efflux pump encoding gene sdrM...Finally, loss of function mutants of the tyrosine recombinase XerC, that is known to play a role in chromosomal separation, were deficient for sdrM amplification, indicating that XerC is a novel modulator of gene amplification, or the maintenance or selection of amplified gene copies. Thus, our work sheds light on genetic factors that alter gene amplification-mediated evolutionary trajectories to antibiotic resistance in S. aureus and can potentially unlock mechanisms by which such evolution of resistance can be inhibited."

Journal • Infectious Disease

The UK Antimicrobial Registry (UKAR): an overview of the first 20 months of recruitment. (PubMed, JAC Antimicrob Resist) - "UKAR is an ongoing prospective registry of adult inpatients prescribed 11 eligible study drugs (cefiderocol, ceftaroline, ceftazidime/avibactam, ceftobiprole, ceftolozane/tazobactam, dalbavancin, delafloxacin, eravacycline, imipenem/cilastatin/relebactam, meropenem/vaborbactam and oritavancin). The UKAR provides real-world data on the use of novel antimicrobials confirming they are sometimes used empirically as well as for directed therapy to treat both complex and common infections, and often for multiresistant pathogens. The study is a novel and important resource to support the judicious use of these drugs."

Journal • Critical care • Infectious Disease • Nephrology • Respiratory Diseases • Septic Shock

Sodium load of novel antibiotics: considerations for nephrologists and clinicians. (PubMed, Int Urol Nephrol) - "Parenteral antibiotics are an often-overlooked contributor to sodium intake. Clinicians should be aware of this hidden source in sodium-sensitive patients such as kidney disease patients. We propose a visual chart to support sodium-conscious antimicrobial selection as part of broader stewardship strategies."

Journal • Review • Chronic Kidney Disease • Nephrology • Renal Disease